A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Bacitracin Zinc and Polymyxin B

First FDA approval2008-04-25
Generic availableYes · 2 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one
Lowest NADAC
$2.78/unit
2 NDCs benchmarked, lowest of all strengths.
Average NADAC
$16.20
Across all dosage forms in distribution.
Highest NADAC
$29.63
Wide spread — brand-strength NDCs still in market.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema7 entries indexed · 4 visible
What is Bacitracin Zinc and Polymyxin B used for?

Bacitracin Zinc and Polymyxin B is a this drug class medication tracked in Medicare Part D.

Is there a generic for Bacitracin Zinc and Polymyxin B?

Yes. 2 ANDAs filed at FDA, 2 generic manufacturers currently shipping.

How much does my plan pay for Bacitracin Zinc and Polymyxin B?

Across 329 Part D plans, Bacitracin Zinc and Polymyxin B averages $16.20/unit (NADAC). Lowest available: $2.78/unit. Highest in distribution: $29.63/unit.

Is Bacitracin Zinc and Polymyxin B on the FDA shortage list?

No. Bacitracin Zinc and Polymyxin B is not currently on the FDA Drug Shortage Database.

3 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (2 approvals on file) · NADAC unit costs: CMS NADAC weekly file (2 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.